Michelle Dawson posts

Post published on Twitter/X on 16 Apr 2023 15:14

Twitter/X DOI work crossref Extract quoted in the post Question asked by Dawson in the post External link integrated into the post

Structured cited links

1 cited resource

DOI work Fetched Post crossref

Hsiang-Yuan Lin, Elia Abi-Jaoude, Pushpal Desarkar, Wei Wang, Stephanie H. Ameis, Meng-Chuan Lai, Yona Lunsky, Tarek K. Rajji (2023). Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial. PLOS ONE, 18(4), e0282114. Public Library of Science (PLoS).

Publication date
12 Apr 2023
Identifier
10.1371/journal.pone.0282114
Authors
Hsiang-Yuan Lin, Elia Abi-Jaoude, Pushpal Desarkar, Wei Wang, Stephanie H. Ameis, Meng-Chuan Lai, Yona Lunsky, Tarek K. Rajji
Source
PLOS ONE
Details
18(4), e0282114
Reference type
article
Publisher
Public Library of Science (PLoS)
Metadata source
crossref

Abstract

Severe behavioral problems (SBPs) are common contributors to morbidity and reduced quality of life for adults with intellectual and developmental disabilities (IDD) and their families. Current medications for SBPs show equivocal effectiveness and are associated with a high risk of side effects. New and safe treatments are urgently needed. While preliminary studies suggest that medical cannabinoids, particularly the synthetic cannabinoid nabilone, are plausible treatment options for SBPs in adults with IDD, data on the tolerability, safety and efficacy of nabilone in this population has never been investigated. Thus, we propose this first-ever Phase I pre-pilot open-label clinical trial to obtain preliminary data on the adherence, tolerability and safety profiles of nabilone in adults with IDD, and explore changes in SBPs pre- to post-treatment. We hypothesize that nabilone has favorable tolerability and safety profile for adults with IDD. The preliminary results will inform the next-stage pilot randomized controlled trials, followed by fully powered clinical trials eventually. This research helps fill the evidence gap in the use of cannabinoids in individuals with IDD to meet the needs of patients, families, and service providers.

Study authors in this cited reference